Trump FDA discounts endangered the development of medicines

President Donald Trump can prevent budget discounts and employees in the Food and Drug Administration that President Donald Trump publishes new drugs “from developing, approving them or marketing them in a timely manner, or at all,” according to dozens of annual reports that pharmaceutical companies sent to the Securities and Stock Exchange Committee in late February.

“The Trump administration has enacted many executive procedures that can impose large burdens, or financial delay, the ability of the FDA to engage in routine organizational and control activities,” says one of the deposits from Xenon Pharmaceutics, a company based in Canada that search for epilepsy treatments. “If these executive procedures impose restrictions on the ability of the FDA to engage in supervision and implementation activities in the natural path, our work may be affected negatively.”

In February, the Ministry of Governmental Efficiency, called Elon Musk, which caused hundreds of FDA employees (FDA), caused widespread panic over the status of grants, active clinical trials, and drug approvals. After a little more than a week, Repeat A handful of employees who organize American food supplies and review medical devices.

This step has not done a little fears from various pharmaceutical companies, who are concerned that any disruption of the slow -motion bureaucracy could cause food and drug management to stop. Before new drugs can go to the market, the Food and Drug Administration must perform regular searches and reviews, a process that may take years. Many recent SEC files say whether the FDA has stopped this work, these medications cannot be simply released.

The biological pharmaceutical company, which develops treatments for a rare form of low blood sugar, says that Doug’s delegation “to reduce expenses” in agencies such as Food and Drug Administration (FDA) will slow down, according to the SEC report. The company adds: “Our business depends on the FDA and the ability of the FDA to respond in time to our drug development activities.”

Some pharmaceutical companies have mentioned Dog’s work in the National Institutes of Health, which provide tens of billions of dollars to research and develop pharmaceuticals for companies and universities worldwide.

“DOGE creates” pressure on uncertainty “about the federal budget, including the debt ceiling, which claims to” negatively affect the economic environment and reduce health and health care spending. “

Some deposits also warned of the possibility of Trump to repair the current drug regulations, which costs additional time and money to comply with it. Trump is a modern Executive order It shows the abolition of restrictions on a large scale through federal agencies, and the new Minister of Health and Humanitarian Services has expressed Robert F. Kennedy Junior for his agreement and Proposal His own budget discounts.

Dog was frozen recently $ 1.5 billion In financing for medical research, then later Get rid of some of Money. The left left between companies is unclear about whether it could eventually expect the United States government to support its research. IBIO, a company based in San Diego, who is studying antibody treatments for obesity and heart disorders, said in a file that is currently “unclear” how Trump’s health care policy will affect grant financing in its field.